netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group
 Search
 Formulary Chapter 4: Central nervous system - Full Chapter
04.08.01  Expand sub section  Control of epilepsy
 note 

Category

Antiepileptic drugs

MHRA Advice

1

phenytoin, carbamazepine, phenobarbital, primidone

For these drugs, doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product

2

valproate, lamotrigine, perampanel, retigabine, rufinamide, clobazam, clonazepam, oxcarbazepine, eslicarbazepine, zonisamide, topiramate

For these drugs, the need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

3

levetiracetam, lacosamide, tiagabine, gabapentin, pregabalin, ethosuximide, vigabatrin  

For these drugs, it is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors

04.08.01  Expand sub section  Carbamazepine and Oxcarbazepine
04.08.01  Expand sub section  Ethosuximide
04.08.01  Expand sub section  Gabapentin and pregabalin
04.08.01  Expand sub section  Lamotrigine to top
04.08.01  Expand sub section  Levetiracetam
04.08.01  Expand sub section  Phenytoin
04.08.01  Expand sub section  Tiagabine
04.08.01  Expand sub section  Topiramate
04.08.01  Expand sub section  Valproate to top
04.08.01  Expand sub section  Vigabatrin
04.08.01  Expand sub section  Zonisamide
04.08.01  Expand sub section  Other Drugs
Perampanel (Fycompa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Perampanel 2mg tablets
Perampanel 4mg tablets
Perampanel 6mg tablets
Perampanel 8mg tablets
Perampanel 10mg tablets
Perampanel 12mg tablets

Restriction: By specialist only
Unnecessary to maintain patient on specific manufacturer's products.

 
Link  NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
   
Retigabine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Retigabine Tablet 50mg
Retigabine Tablet 100mg
Retigabine Tablet 200mg
Retigabine Tablet 300mg
Retigabine Tablet 400mg

Retigabine for the adjunctive treatment of partial onset seizures in epilepsy, see TA232.

Discontinued June 2017See manufacturer's note

 
Link  NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
   
Rufinamide (Inovelon®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Rufinamide Tablet 100mg
Rufinamide Tablet 200mg
Rufinamide Tablet 400mg
Rufinamide Oral Suspension 40mg/1ml S/F

Restriction: Initiation and stabilisation by specialist
Unnecessary to maintain patient on specific manufacturer's products

 
   
 ....
 Non Formulary Items
Acetazolamide

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs which require special consideration. These are drugs for Consultant Prescribing ONLY. They should not be prescribed in Primary Care.  

Amber

Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care. For some drugs there may be a Ricad in place to aid the transition to primary care.  

Amber E

Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care but also require and ESCA (Shared Care Agreement)   

Green

Suitable first-line drugs for implementation in Primary Care  

On Formulary

South Staffs Formulary Choice  

netFormulary